ArticleAnnals of translational medicine2022
Effects of Endothelin-1 and nitric oxide levels on myocardial ischemia-reperfusion injury.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Development and validation of a risk prediction model for myocardial hypoperfusion after primary PCI in ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Risk management and empirical study of the doctor-patient relationship: based on 1790 litigation cases of medical damage liability disputes in China.BMC health services research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To study the role of nitric oxide (NO) in myocardial ischemia-reperfusion injury (IRI) and Endothelin-1 (ET-1) in the process of reperfusion in an animal model. ET is a strong vasoconstrictor peptide, which is closely related to the physiological and pathological state of the cardiovascular system. ET not only directly stimulates and activates a variety of hormones and cytokines, but also is one of the mediators promoting myocardial remodeling, and participates in and promotes myocardial ischemia injury. Methods: Before myocardial ischemia, Krebs-Henseleit (KH) perfusion solution containing different concentrations of L-arginine (LA; substrate of NO) were given to 6 groups of rats, and ET was given at the early stage of reperfusion in 3 groups. During reperfusion, cardiac function indexes, myocardial enzyme release and NO content in coronary effluent, and the cardiac malondialdehyde (MDA) content was measured. The myocardial ultrastructure was observed by microscopy. Data of each group are expressed as mean ± standard deviation, and the baseline value of each group before ischemia was the recovery value during reperfusion. SPSS26.0 (IBM, Chicago, USA) was used for statistical processing. Results: Before myocardial ischemia, infusion of KH solution containing a low concentration of LA (10 mmol/L) reduced myocardial IRI, whereas infusion of a KH solution containing high concentration of LA (100 mmol/L) before ischemia significantly aggravated myocardial IRI. The administration of KH solution containing LA and ET-1 (1,000 mmol/L) significantly reduced myocardial IRI. Conclusions: NO plays a dual role in myocardial ischemia-reperfusion, both beneficial and harmful. The combination of NO and ET-1 can reduce the toxic effect of NO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.